Search

Zentalis Pharmaceuticals Inc

Lezárt

4.08 8.22

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.68

Maximum

3.87

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+134.22% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

25M

356M

Előző nyitás

-4.14

Előző zárás

4.08

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 2. 23:56 UTC

Fidelity National Financial shares are higher in after-market trading, recovering from earlier losses but remain below the 20-day moving average.

2026. szept. 2. 23:56 UTC

MGM Resorts International shares are higher in after-market trading, supported by a broader market response to weaker ADP private payrolls data.

2026. szept. 2. 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2026. szept. 2. 23:56 UTC

Correlated Moves

Equinix Inc. shares are higher in after-market trading, supported by a weaker ADP payrolls report indicating lower job growth than expected.

2026. szept. 2. 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

2026. szept. 2. 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

2026. szept. 2. 23:56 UTC

APA Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by weaker ADP payroll data, easing rate hike concerns.

2026. szept. 2. 23:56 UTC

Abbott Laboratories shares are lower in after-market hours, reflecting a decline since Wednesday's close amid weaker-than-expected job growth reported by ADP.

2026. szept. 2. 23:56 UTC

Union Pacific Corp shares are lower in after-market hours amid volatility, following disappointing ADP payroll data that may affect Federal Reserve interest rate expectations.

2026. szept. 2. 23:56 UTC

T Rowe Price Group Inc shares are trading lower in after-market hours following a volatile session amid reactions to weaker-than-expected ADP payroll data.

2026. szept. 2. 23:52 UTC

Mexico's inflation rate expected to stabilize around 3% amid cautious market sentiment and external risks ahead of September release.

2026. szept. 2. 23:52 UTC

Mexican Inflation Data Release on September 9, Amid Cautious Optimism and Ongoing Economic Risks.

2026. szept. 2. 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, 2026, amid mixed sentiments and rising economic pressures.

2026. szept. 2. 23:52 UTC

US ISM Services PMI Expected to Rise Slightly to 54.3, Indicating Continued Expansion Amid Economic Challenges

2026. szept. 2. 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious optimism and external inflation risks on September 8, 2026.

2026. szept. 2. 23:51 UTC

Dorian LPG Ltd shares are lower in after-market hours, following five consecutive sessions of gains. The decline coincides with a weaker ADP payrolls report.

2026. szept. 2. 23:51 UTC

Hackett Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and trading below their 20-day moving average.

2026. szept. 2. 23:51 UTC

Champion Homes Inc is rising in after-market trading, supported by gains in the Homebuilding sub-sector. The asset has recovered from earlier session lows.

2026. szept. 2. 23:51 UTC

Essential Properties Realty Trust shares are higher in after-market trading. Broader market trends and recent economic data may be influencing this movement.

2026. szept. 2. 23:51 UTC

ETF Constituents
Macro News

State Street Financial Select Sector SPDR ETF rises in after-market hours as weaker job growth eases Fed rate hike concerns and key holdings perform well.

2026. szept. 2. 23:51 UTC

IQVIA Holdings Inc shares rose in after-market trading, continuing upward momentum amid a broader macroeconomic backdrop following the ADP payrolls report.

2026. szept. 2. 23:51 UTC

Correlated Moves

Republic Bancorp Inc shares declined in after-hours trading, reflecting broader financial sector weakness amid disappointing job creation data from the ADP report.

2026. szept. 2. 23:51 UTC

South Plains Financial Inc is trading lower in after-market hours, continuing a trend seen during the regular session amid broader market weakness following a disappointing ADP report.

2026. szept. 2. 23:51 UTC

Keysight Technologies Inc shares are lower in after-market hours, continuing a decline from earlier in the session amid a challenging trading environment.

2026. szept. 2. 23:51 UTC

Sylvamo Corp shares are lower in after-market trading, continuing a decline from earlier in the session amid broader market weakness following the ADP payrolls report.

2026. szept. 2. 23:51 UTC

Maximus Inc shares are higher in after-market trading, rebounding from earlier lows. Weaker ADP payroll data may ease concerns over aggressive Fed rate hikes.

2026. szept. 2. 23:51 UTC

New York Times Co shares are higher in after-market trading, supported by a solid market backdrop and recent ADP payrolls report indicating slower job growth.

2026. szept. 2. 23:51 UTC

Best Buy Co Inc shares are higher in after-market trading, supported by gains in the Computer & Electronics Retail sub-sector and maintaining a notable high.

2026. szept. 2. 23:51 UTC

U.S. equity indices rebound amid weak job growth and rising oil prices, while geopolitical tensions and climbing bond yields raise inflation concerns.

2026. szept. 2. 23:51 UTC

Asian equity markets decline amid U.S.-Iran tensions and rising bond yields, while U.S. stocks rebound ahead of key jobs data impacting Fed rate outlook.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

134.22% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  134.22%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat